Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 13/20 | 0.57 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19982124 | 0.93 | CYP3A4 (0.53) | YAP1ACECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22929113 | 0.90 | ACE (0.46) | YAP1ACECYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19982078 | 0.89 | YAP1 (0.72) | YAP1ACE | |
| SCHEMBL19982123 | 0.88 | STAT3 (0.47) | ACECYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19975035 | 0.85 | YAP1 (0.62) | YAP1PPARGCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19974578 | 0.85 | ALDH1A1 (0.55) | ACE | |
| SCHEMBL19975033 | 0.85 | YAP1 (0.62) | YAP1PPARGCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22929163 | 0.84 | ACE (0.47) | ACECYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22929115 | 0.81 | ITGB1 (0.46) | ACE | |
| SCHEMBL19982179 | 0.81 | YAP1 (0.59) | YAP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999695-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210130297-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10906874-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2018053446-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906874-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, IWS1, YES1 | YAP1 1/4885ACE 4580/4885PPARG 3505/4885 |
| US-20210130297-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, YES1, MYC | YAP1 1/4885ACE 4409/4885PPARG 3840/4885 |
| US-11999695-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, YES1, MYC | YAP1 1/4885ACE 4394/4885PPARG 3995/4885 |
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, YES1, MYC | YAP1 1/4885ACE 4394/4885PPARG 3995/4885 |
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | YAP1, YES1, MYC | YAP1 1/4885ACE 4409/4885PPARG 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.